Information Provided By: 
Fly News Breaks for June 24, 2019
CNCE
Jun 24, 2019 | 07:53 EDT
As previously reported, SunTrust analyst Joon Lee initiated Concert Pharmaceuticals with a Buy rating and $30 price target. In a research note to investors, Lee contends that Concert's CTP-692 is one of the most differentiated and promising, yet under-appreciated drugs in development for schizophrenia. The analyst thinks the drug's period of remaining under the market's radar will be short-lived.
News For CNCE From the Last 2 Days
There are no results for your query CNCE
